Endocyte Inc., 3000 Kent Ave., Suite A1-100, West Lafayette 47906, is a biopharmaceutical company developing therapies for the treatment of cancer and inflammatory diseases. In 2011, Endocyte lost $40.5 million, or $1.40 a share, on $191,000 in revenue. A year earlier, the company lost $20.1 million, or $21.77 a share, on no revenue. The company’s website is www.endocyte.com. Endocyte launched its initial public offering at $6 a share in February 2011. The stock trades on Nasdaq under the ticker EYCT. Information for Proxy Corner was taken from Yahoo! Finance and from the company’s proxy statement dated April 13, 2012. View full Proxy Corner feature.
Please enable JavaScript to view this content.